CRDF: מחיר חזוי לרווח Cardiff Oncology Corp

The investment profile of Cardiff Oncology, Inc. (CRDF) is marked by high volatility due to its dependence on the outcome of onvansertib trials and R&D losses. To optimize the development of agents against solid tumors, the business relies on external manufacturing and logistics contractors. The Forward P/E valuation characteristic is 0.00. Cardiff Oncology, Inc. (CRDF) is creating a broad spectrum of antitumor agents, without limiting itself to a single technological platform or a narrow therapy modality.
פילוחי מדדים ואנליטיקה של חברת cardiffoncology.com (CRDF)

The indicator's dynamics are driven by the market value's sensitivity to future net profit forecasts. This ratio measures investors' willingness to pay a premium for every dollar of expected income when assessing the asset's fundamental value. For Cardiff Oncology, Inc. (CRDF), which is developing a PLK1 inhibitor, the calculation is based on hypotheses regarding the commercialization of targeted therapy. By analyzing the company's forward P/E ratio, one can identify hidden market expectations. The stability of this chart often foreshadows a sharp revision in capitalization.